Press Releases

Indivior Announces H1 and Q2 2022 Financial Results

Slough, UK, and Richmond, VA, July 28, 2022 - Indivior PLC (LON: INDV) today announced its financial results for the period ending June 30, 2022. The earnings release, investor presentation and webcast are available at

Download full H1 and Q2 2022 Financial Results

The investor presentation can be found at by 7:00 a.m. EDT July 28, 2022

There will be a live webcast presentation at 13:00 BST (8:00 a.m. EDT) hosted by Mark Crossley, CEO. The details are below.

(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration) 


About Indivior

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid use disorder treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and cooccurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting

Media Contacts:

Tulchan Communications
+44 207-353-4200

+1 804-594-0836

Investor Contacts:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123

Tim Owens
Director, Investor Relations
Tel: 804-263-3978